- Fee assured
- Verified this account
I have wide experience in the management of these cancers. I have active clinical research interests and have published widely. I trained in medicine at St Georges Hospital, London and in Oncology at the Royal Marsden, Hammersmith and Charing Cross Hospitals. I undertook a laboratory based MD thesis. I was a research fellow/consultant in Sydney for 18 months prior to my consultant appointment at Cambridge in 2001.
Areas of interest
Kidney (renal) cancer: use of tyrosine kinase inhibitors eg Sutent and other drugs.
Skin cancer: advanced basal cell carcinomas Erivedge (vismodegib) therapy. Radiotherapy for skin cancers and melanoma.
Rare skin cancers such as Primary Cutaneous lymphomas; Kaposis sarcoma; Merkels cell cancer.
Current NHS consultant posts held
Consultant Clinical Oncolgist, Addenbrookes Hospital Cambridge
Clinical trials in renal and skin cancer.
Frequent attendance and presentations at National and International meetings.
I have published in many journals inculding Lancet Oncology, Journal of Clinical Oncology and New England Journal of Medicine.
- MB BS St Georges, University of London 1987
- FRCP Royal College of Physicains of London 2010
- FRCR UK 1995
- FRANZCR Australia 2000
- MD University of London 1998
Professional bodies (positions held - last 3 yrs)
- Renal Cancer Clinical studies Group NCRI 2012
- Spire Cambridge Lea Hospital, CB24 9EL
- 18:30 - 20:00
- 01223 216364
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.
Information for healthcare professionals (Bupa patients only, last 12 months)
Clinical supervision and planning for delivery of chemotherapy cycle 1 - 28 days - (5-50)
Spire Cambridge Lea Hospital (5-50)
Clinical supervision and planning for delivery of chemotherapy cycle in the member's home 1-28 days - (5-50)
Clinical supervision of the planning of a course of simple radiotherapy - (1-5)
Clinical supervision of external beam radiotherapy, up to and including 15 fractions or part thereof - (1-5)